Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced nonsquamous non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Authors
Wai Lin Thein
University of Medicine, Brooklyn, NY
Wai Lin Thein, Aung Tun, Elizabeth Guevara, Aymen Elfiky, James Gasperino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 125)
DOI
10.1200/JCO.2019.37.8_suppl.125
Abstract #
125
Poster Bd #
H9
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
First Author: Aung Tun
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
First Author: Aung Tun
Poster
2020 ASCO Virtual Scientific Program
Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.
First Author: Ranjan Pathak
Poster
2020 ASCO Virtual Scientific Program
Is there a benefit of immune checkpoint inhibitors for patients over 75 years of age with advanced cancer in first and second line setting: A meta-analysis.
First Author: Thierry Landre